The administration of immunostimulatory oligonucleotide sequences (ISS-ODN, also known as CpG-ODN) inhibits experimental asthma. This protective effect is transient and lasts for a few weeks. We recently identified that ISS-ODN induces high levels of pulmonary indoleamine 2,3-dioxygenase (IDO), a key enzyme of tryptophan (Trp) metabolism. Our preliminary data suggest that IDO may protect against experimental asthma by inducing apoptosis of antigen (i.e., allergen) stimulated Th2 cells via Trp deprivation in an organ-specific fashion (i.e., lung specific). Based on our observation and aligned with the exploratory nature of this RFA--specifically the identification of mechanisms by which known biological agents induce and/or maintain immune tolerance--we have put together two specific aims (SA). Thus, in SA-1 we hypothesize that the induction of transient tolerance is due to the depletion of antigen-specific pulmonary Th2 cells and that homeostatic proliferation, which replenishes this population with time, accounts for the re-emergence of the asthmatic phenotype. Recent published data indicate that IDO expressing antigen presenting cells (APCs) mediate a regulatory role on T cell responses and support the development of T regulatory (Treg) cells. Thus, in SA-2 we hypothesize that under the conditions of repeated ISS administration to chronically OVA-challenged mice an antigen specific and a long-term tolerance is developed secondary to the generation of Treg cells and their recruitment into the lungs. We will validate these hypotheses in a series of experiments in vivo using (1) an adoptive transfer-based approach of in-vitro differentiated, OVA-specific, transgenic Th2 cells to wt mice and (2) OVA/alum sensitized mice. The results of the proposed studies will offer new insight into controlling immune tolerance by providing the molecular/biochemical basis for tolerance induction by ISS-ODN. Furthermore, these results will help to optimize the therapeutic effects of ISS-ODN in coming clinical trials in patients with allergic asthma.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL079449-01
Application #
6779612
Study Section
Special Emphasis Panel (ZAI1-PTM-I (J3))
Program Officer
Noel, Patricia
Project Start
2004-07-12
Project End
2006-06-30
Budget Start
2004-07-12
Budget End
2005-06-30
Support Year
1
Fiscal Year
2004
Total Cost
$230,250
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hayashi, Tomoko; Mo, Ji-Hun; Gong, Xing et al. (2007) 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci U S A 104:18619-24
Raz, Eyal (2007) Organ-specific regulation of innate immunity. Nat Immunol 8:3-4
Takabayshi, Kenji; Corr, Maripat; Hayashi, Tomoko et al. (2006) Induction of a homeostatic circuit in lung tissue by microbial compounds. Immunity 24:475-87
Hayashi, Tomoko; Raz, Eyal (2006) TLR9-based immunotherapy for allergic disease. Am J Med 119:897.e1-6
Hayashi, Tomoko; Gong, Xing; Rossetto, Cyprian et al. (2005) Induction and inhibition of the Th2 phenotype spread: implications for childhood asthma. J Immunol 174:5864-73
Horner, Anthony A; Redecke, Vanessa; Raz, Eyal (2004) Toll-like receptor ligands: hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol 4:555-61